Sanders Morris Harris LLC lowered its position in shares of Intrexon Corp (NYSE:XON) by 98.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,807 shares of the biotechnology company’s stock after selling 127,393 shares during the period. Sanders Morris Harris LLC’s holdings in Intrexon were worth $181,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently made changes to their positions in XON. BlackRock Inc. increased its position in shares of Intrexon by 76.8% during the second quarter. BlackRock Inc. now owns 4,647,554 shares of the biotechnology company’s stock valued at $64,788,000 after acquiring an additional 2,019,142 shares in the last quarter. Summit Trail Advisors LLC increased its position in shares of Intrexon by 1,777.4% during the first quarter. Summit Trail Advisors LLC now owns 587,048 shares of the biotechnology company’s stock valued at $587,000 after acquiring an additional 555,779 shares in the last quarter. Northern Trust Corp increased its position in shares of Intrexon by 123.1% during the second quarter. Northern Trust Corp now owns 917,510 shares of the biotechnology company’s stock valued at $12,791,000 after acquiring an additional 506,186 shares in the last quarter. MSD Partners L.P. bought a new stake in shares of Intrexon during the first quarter valued at approximately $6,132,000. Finally, UBS Group AG increased its position in shares of Intrexon by 114.0% during the first quarter. UBS Group AG now owns 424,053 shares of the biotechnology company’s stock valued at $6,501,000 after acquiring an additional 225,905 shares in the last quarter. 84.92% of the stock is owned by institutional investors.
Several equities research analysts recently weighed in on XON shares. Bank of America downgraded shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price target for the company. in a research report on Monday, July 16th. Zacks Investment Research downgraded shares of Intrexon from a “buy” rating to a “hold” rating in a research report on Monday, July 16th. Stifel Nicolaus started coverage on shares of Intrexon in a research report on Tuesday, July 17th. They issued a “buy” rating and a $72.00 target price for the company. Finally, ValuEngine raised shares of Intrexon from a “strong sell” rating to a “sell” rating in a research report on Monday, August 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. Intrexon presently has an average rating of “Hold” and an average target price of $27.00.
In other Intrexon news, insider Helen Sabzevari sold 8,402 shares of Intrexon stock in a transaction that occurred on Wednesday, July 18th. The shares were sold at an average price of $14.54, for a total value of $122,165.08. Following the completion of the sale, the insider now owns 25,000 shares of the company’s stock, valued at approximately $363,500. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 48.20% of the company’s stock.
NYSE:XON traded down $0.06 during trading hours on Tuesday, reaching $16.05. The company had a trading volume of 14,203 shares, compared to its average volume of 1,584,055. The company has a current ratio of 1.78, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01. Intrexon Corp has a 52 week low of $10.26 and a 52 week high of $20.16. The company has a market cap of $2.47 billion, a PE ratio of -17.55 and a beta of 1.09.
Intrexon (NYSE:XON) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.28). Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. The company had revenue of $45.30 million during the quarter, compared to the consensus estimate of $51.70 million. During the same period last year, the firm posted ($0.16) EPS. Research analysts forecast that Intrexon Corp will post -0.79 earnings per share for the current year.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Featured Story: Trading Strategy Examples and Plans
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.